INNOVACAP logo

Innova Captab Limited Stock Price

NSEI:INNOVACAP Community·₹47.8b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author

INNOVACAP Share Price Performance

₹835.20
99.55 (13.53%)
22.4% undervalued intrinsic discount
₹1,076.00
Fair Value
₹835.20
99.55 (13.53%)
22.4% undervalued intrinsic discount
₹1,076.00
Fair Value
Price ₹835.20
AnalystConsensusTarget ₹1,076.00

INNOVACAP Community Narratives

AnalystConsensusTarget·
Fair Value ₹1.08k 22.4% undervalued intrinsic discount

New Jammu Facility Will Capture Global Healthcare Demand

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative

Recent INNOVACAP News & Updates

New Jammu Facility Will Capture Global Healthcare Demand

Key Takeaways New state-of-the-art facility and expansion into branded generics and CDMO deepen client relationships and position the company for sustainable global revenue growth. Backward integration, cost-plus pricing, and R&D into specialized products are expected to drive margin improvement and long-term earnings stability.

A Look At The Intrinsic Value Of Innova Captab Limited (NSE:INNOVACAP)

Jun 20
A Look At The Intrinsic Value Of Innova Captab Limited (NSE:INNOVACAP)

Additional Considerations Required While Assessing Innova Captab's (NSE:INNOVACAP) Strong Earnings

May 26
Additional Considerations Required While Assessing Innova Captab's (NSE:INNOVACAP) Strong Earnings

Innova Captab Limited (NSE:INNOVACAP) Just Released Its Full-Year Earnings: Here's What Analysts Think

May 23
Innova Captab Limited (NSE:INNOVACAP) Just Released Its Full-Year Earnings: Here's What Analysts Think

Innova Captab Limited's (NSE:INNOVACAP) Intrinsic Value Is Potentially 26% Below Its Share Price

Mar 12
Innova Captab Limited's (NSE:INNOVACAP) Intrinsic Value Is Potentially 26% Below Its Share Price

Innova Captab Limited Key Details

₹13.0b

Revenue

₹8.4b

Cost of Revenue

₹4.6b

Gross Profit

₹3.3b

Other Expenses

₹1.3b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
22.68
Gross Margin
35.09%
Net Profit Margin
9.98%
Debt/Equity Ratio
35.2%

Innova Captab Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

High growth potential with excellent balance sheet.

0 Risks
3 Rewards

About INNOVACAP

Founded
2005
Employees
n/a
CEO
Vinay Lohariwala
WebsiteView website
innovacaptab.com

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Indian Market Performance

  • 7 Days: 1.8%
  • 3 Months: -1.3%
  • 1 Year: -2.3%
  • Year to Date: 1.1%
Over the last 7 days, the market has risen 1.8%, driven by gains of 2.6% in the Financials sector. In the last 12 months, the market has been flat. Earnings are forecast to grow by 16% annually. Market details ›